The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Follow-up CAR T-cell data so far
The first relatively long-term CAR T-cell trial follow-up data came out at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Speaking from the meeting, Tanya Siddiqi, MD, of the City of Hope National Medical Center, Duarte, CA, discusses the ZUMA-1 (NCT02348216) study of the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel; KTE-C19). Dr Siddiqi discusses the long-term data thus far on remission, response durability and toxicity.
